The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway | Zendy

Yang Zhou | Zendy; Wei Wu | Zendy

Open Access

The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway

Author(s) -

Yang Zhou,

Wei Wu

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000475942

Subject(s) - empagliflozin , diabetic cardiomyopathy , endocrinology , medicine , empa , western blot , chop , endoplasmic reticulum , cardiomyopathy , pharmacology , diabetes mellitus , chemistry , heart failure , type 2 diabetes , biochemistry , mineralogy , lymphoma , electron microprobe , gene

This study aimed to determine whether or not the sodium-glucose co-transporter 2 inhibitor, empagliflozin (EMPA), can protect against diabetic cardiomyopathy (DCM) and to elucidate the related mechanism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research